Related Experiment Videos
AcSDKP plasma concentrations in patients with solid tumours: comparison of two chemotherapeutic regimens
1Laboratoire d and apos;Hèmatologie Experimentale, Faculté de Médecine,Limoges, France.
Abstract:
The tetrapeptide AcSer-Asp-Lys-Pro (AcSDKP) is a physiological inhibitor of the proliferation of haematopoietic stem cells and progenitors. In Ara-C-treated mice, its plasmatic concentrations decrease while the CFU-S start cycling. Infusion of synthetic AcSDKP (Goralatide) at this time protects them from haematoxicity by blocking early cycling of CFU-S. Both in vitro and in vivo, this effect seems to be optimal in a narrow range of concentrations. Thus, a better knowledge of the kinetics of endogenous AcSDKP during cancer treatment could help to optimize the treatments with Goralatide. AcSDKP plasma levels have been measured by a specific EIA in 14 cancer patients during the two initial monthly 5 day courses of chemotherapy with 5-FU alone administered either by continuous infusions (six patients) or by 1 h daily infusions (eight patients). AcSDKP concentrations did not vary significantly during the first and the second course. Together with our previous results in AML patients treated with high doses chemotherapy (Ara-C and Anthracyclin), our present data suggest that the variations of endogenous AcSDKP in patients are dependent of the type, doses and schedule of chemotherapy.
Insights
The tetrapeptide AcSer-Asp-Lys-Pro (AcSDKP) inhibits stem cell proliferation. Cancer chemotherapy did not significantly alter AcSDKP plasma levels in patients, suggesting chemotherapy type influences AcSDKP variations.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- AcSer-Asp-Lys-Pro (AcSDKP) is a natural inhibitor of hematopoietic stem and progenitor cell proliferation.
- AcSDKP levels decrease during chemotherapy in mice, correlating with stem cell cycling and potential toxicity.
- Goralatide, synthetic AcSDKP, can protect stem cells from chemotherapy-induced toxicity by blocking early cycling.
Purpose of the Study:
- To investigate the impact of 5-fluorouracil (5-FU) chemotherapy on endogenous AcSDKP plasma levels in cancer patients.
- To determine if AcSDKP levels vary significantly during different 5-FU administration schedules (continuous vs. daily infusion).
- To contribute to optimizing Goralatide treatment strategies by understanding AcSDKP pharmacokinetics during cancer therapy.
Main Methods:
- Measurement of AcSDKP plasma concentrations using a specific enzyme immunoassay (EIA).
- Analysis of 14 cancer patients undergoing two initial monthly 5-day courses of 5-FU chemotherapy.
- Comparison of AcSDKP levels between patients receiving continuous infusion 5-FU (n=6) and 1-hour daily infusion 5-FU (n=8).
Main Results:
- AcSDKP plasma concentrations showed no significant variation during the first and second 5-FU chemotherapy courses in all patients.
- No significant difference in AcSDKP levels was observed between the continuous infusion and daily infusion 5-FU groups.
- Previous findings in AML patients treated with high-dose Ara-C and Anthracyclin showed different AcSDKP variations.
Conclusions:
- The type, dose, and schedule of chemotherapy appear to influence the variations of endogenous AcSDKP levels in cancer patients.
- 5-FU chemotherapy, administered as studied, does not induce significant changes in AcSDKP plasma concentrations.
- Further research is needed to elucidate the complex relationship between chemotherapy regimens and AcSDKP kinetics for potential therapeutic optimization.